Analysts at Oppenheimer initiated coverage on Ocular Therapeutix (OCUL) with a ‘Outperform’ rating and a $25 price target in a research report issued to clients on Tuesday. The firm sees the company as an appealing platform play in the ophthalmology space, and believes that at current levels even a conservative view of peak share suggests significant upside. Ocular shares were also initiated this morning with a ‘Outperform’ rating and a $21 price target at RBC Capital Markets.
Shares of Ocular Therapeutix traded as high as $14.41 Monday, before ending the day at $14.02. In the past 52 weeks, OCUL has traded between a low of $11.90 and a high of $15.25, which is more than 28% above that low price. Over the past week alone the stock has gained 7.50%. Ticker is up 8.97% on a year-over-year basis.
The chart below shows where the stock has traded over the last year, with the 50-day and 200-day moving averages included.
Ocular Therapeutix, Inc is a development stage biopharmaceutical company, focused on the development and commercialization of ophthalmic therapeutic products. The firm was founded in 2006 and is headquartered in Bedford, Massachusetts.